Combined treatment with cetuximab and RUNX3 re-expression significantly suppressed the growth of NSCLC cells compared with treatment with cetuximab and RUNX3 re-expression alone (Fig. 5D). The gene discussed is RUNX3; the disease is non-small cell lung carcinoma.